英国房颤口服抗凝处方变化对临床与预算的影响
该研究基于英格兰全国数据库,比较2011年1月至2014年6月与2014年7月至2017年12月两个时段房颤患病率、房颤相关卒中住院发生率及口服抗凝处方的变化。结果显示口服抗凝接受者增加86.5%,DOAC处方量大幅上升,处方费用总体上升781.2%,但房颤相关卒中发生率下降11.3%,使每例患者总体费用由1129英镑降至840英镑,增量节约289英镑。
要点
- DOAC处方项数增幅2004.8%(95%CI 1848.8%至2160.7%)。
- 调整房颤患病率后房颤相关卒中下降11.3%(95%CI -11.5%至-11.1%)。
核心结论
- 尽管DOAC处方增加近百万张且相关支出大幅上升,房颤相关卒中下降仍在全国层面带来增量节约。
研究设计与样本
- 研究基于英格兰全国数据库,获取全科诊所、医院及注册患者的房颤患病率、房颤相关卒中住院发生率和处方数据,卒中照护成本采用已发表数据。
- 比较2011年1月至2014年6月与2014年7月至2017年12月两个时段的临床与预算变化。
主要发现
- 华法林处方项数增加5.9%(95%CI 2.9%至8.9%),DOAC增加2004.8%(95%CI 1848.8%至2160.7%)。
临床怎么用
- 评估房颤抗凝处方变化时应同时关注卒中发生率与总体照护成本,而不仅看药物支出。
- DOAC处方快速增长伴随费用上升,但卒中下降可在全国层面抵消部分增量支出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess temporal clinical and budget impacts of changes in atrial fibrillation (AF)-related prescribing in England. METHODS: Data on AF prevalence, AF-related stroke incidence and prescribing for all National Health Service general practices, hospitals and registered patients with hospitalised AF-related stroke in England were obtained from national databases. Stroke care costs were based on published data. We compared changes in oral anticoagulation prescribing (warfarin or direct oral anticoagulants (DOACs)), incidence of hospitalised AF-related stroke, and associated overall and per-patient costs in the periods January 2011-June 2014 and July 2014-December 2017. RESULTS: Between 2011-2014 and 2014-2017, recipients of oral anticoagulation for AF increased by 86.5% from 1 381 170 to 2 575 669. The number of patients prescribed warfarin grew by 16.1% from 1 313 544 to 1 525 674 and those taking DOACs by 1452.7% from 67 626 to 1 049 995. Prescribed items increased by 5.9% for warfarin (95% CI 2.9% to 8.9%) but by 2004.8% for DOACs (95% CI 1848.8% to 2160.7%). Oral anticoagulation prescription cost rose overall by 781.2%, from £87 313 310 to £769 444 028, (£733,466,204 with warfarin monitoring) and per patient by 50.7%, from £293 to £442, giving an incremental cost of £149. Nevertheless, as AF-related stroke incidence fell by 11.3% (95% CI -11.5% to -11.1%) from 86 467 in 2011-2014 to 76 730 in 2014-2017 with adjustment for AF prevalence, the overall per-patient cost reduced from £1129 to £840, giving an incremental per-patient saving of £289. CONCLUSIONS: Despite nearly one million additional DOAC prescriptions and substantial associated spending in the latter part of this study, the decline in AF-related stroke led to incremental savings at the national level.
引用
- Orlowski A, Gale CP, Ashton R, et al. Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation. Heart. 2020. PMID: 33122302. doi:10.1136/heartjnl-2020-317006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。